To estimate prescribing tends of and correlates independently associated with high-risk anticholinergic prescriptions in adults aged 65 and older in officebased outpatient visits. DESIGN: Repeated cross-sectional analysis. SETTING: National Ambulatory Medical Care Survey (NAMCS). PARTICIPANTS: A national sample of office-based physician visits by adults aged 65 and older from 2006 to 2015 (n596,996 unweighted). MEASUREMENTS: Prescriptions of high-risk anticholinergics, regardless of indication, were identified, and overall prescribing trends were estimated from 2006 to 2015. Stratified analyses of prescribing trends according to physician specialty and anticholinergic drug class were also performed. We used a multivariable logistic regression analysis to estimate the odds of high-risk anticholinergic prescription. RESULTS: Between 2006 and 2015, a high-risk anticholinergic prescription was listed for 5,876 (6.2%) 96,996 visits of older adults, representative of 14.6 million total visits nationally. The most common drug classes were antidepressants, antimuscarinics, and antihistamines, which accounted for more than 70% of prescribed anticholinergics. Correlates independently associated with greater odds of receiving a high-risk anticholinergic prescription were female sex, the Southern geographic region, specific physician specialties (e.g., psychiatry, urology), receipt of 6 or more concomitantly prescribed medications, and related clinical diagnoses (e.g., urinary continence) (p<.01 for all). CONCLUSION: The prevalence of high-risk anticholinergic prescriptions was stable over time but varied according to physician specialty and drug class. Quality prescribing should be promoted because safer alternatives are available.
D espite a range of clinical indications, medications with anticholinergic properties pose a number of risks to older adults. These agents are commonly prescribed for allergies, obstructive pulmonary disease, and urge urinary incontinence, 1,2 but they are associated with risks of serious adverse events, including cognitive impairment, falls, dementia, and death in older adults. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] This vulnerability to adverse events is due in large part to a variety of aging-related physiological changes such as poor hepatic and renal function and blood-brain barrier permeability. 13 Although some of these medications rely directly on anticholinergic action for their therapeutic effect (e.g., antispasmodics for irritable bowel syndrome and antimuscarinics for urge urinary incontinence), 14 others have anticholinergic side effects separate from their therapeutic action (e.g., antidepressants and antihistamines).
To promote safer prescribing, the recent Beers criteria identified 52 specific strong, high-risk anticholinergic agents in 9 major drug classes as potentially inappropriate medications in older adults and recommended avoidance of 35 of these 52 drugs regardless of indication. 4 On the basis of a strong recommendation grounded in systematic reviews of clinical studies, these 35 anticholinergic drugs are to be avoided regardless of indication. 4 Previous studies investigated anticholinergic use at the national level but relied on self-reported survey questionnaires from civilians and used old data and older versions of the Beers criteria. 11, 15 Furthermore, these studies were conducted cross-sectionally such that they did not investigate secular trends of prescribing over time. With updated Beers criteria and up-to-date nationally representative survey data collected from physicians from 2006 to 2015, we investigated whether prescribing patterns have changed over time and whether these patterns vary according to physician specialty and anticholinergic class. We also estimated demographic and clinical correlates independently associated with these high-risk anticholinergic medication prescriptions.
METHODS

Data Source and Study Sample
We used data from the 2006 to 2015 National Ambulatory Medical Care Surveys (NAMCS), an annual crosssectional survey of office-based physician visits. The NAMCS nationally represents ambulatory medical care services, including prescription trends. 16 We limited our sample to all visits by adults aged 65 and older (N5102,806 unweighted). We excluded observations with any missing covariates (5.7%), which were missing at random according to the Little test, 17 leaving a final sample size of 96,996. Because it used publicly available deidentified data, this study was exempted from institutional review board review (#2000021850) at Yale University School of Medicine because no direct human subjects were involved. Further details of the survey, including descriptions, questionnaires, sampling methodology, and datasets, are publicly available on the NAMCS website. 16 
Measures
High-risk anticholinergic medications. We examined the first 8 medications listed as prescribed for each visit, ensuring consistency across years. Based on Beers criteria and the Rudolph anticholinergic risk scale, 4, 18 we characterized use of 35 high-risk anticholinergic medications with recommendations for complete avoidance: antidepressants (amitriptyline, amoxapine, clomipramine, desipramine, imipramine, nortriptyline, paroxetine, protriptyline, trimipramine), antimuscarinics (darifenacin, fesoterodine, flavoxate, oxybutynin, solifenacin, tolterodine, trospium), antihistamines (brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, dexbrompheniramine, dexchlorpheniramine, dimenhydrinate, doxylamine, hydroxyzine, meclizine, triprolidine), skeletal muscle relaxants (cyclobenzaprine, orphenadrine), and antispasmodics (belladonna alkaloids, clidinium-chlordiazepoxide, dicyclomine, hyoscyamine, propantheline). 
Clinical Diagnoses
Covariates
Similar to prior work on potentially inappropriate prescriptions, we selected covariates based on the potential for clinically relevant confounding. 20, 21 We included the following demographic variables: age (65-74, 74-85, 85), sex, race and ethnicity (non-Hispanic white, nonHispanic black, Hispanic, other), geographic region (Northeast, Midwest, South, West), primary source of payment (private, Medicare, Medicaid, other), reason for visit (acute problem, routine chronic problem, preventive care, pre-or postsurgery care), and number of repeat visits within the past 12 months (0, 1-2, 3-5, 6). For clinical characteristics, variables included 20, 21 physician specialty (primary care, psychiatry, neurology, urology, other), time spent with a doctor (in minutes), number of chronic conditions (<2, 2), and number of concomitant medications prescribed (<6, 6).
Data Analysis
We determined whether demographic and clinical characteristics differed according to anticholinergic prescription status using Bonferroni-adjusted bivariate analyses. Then, we assessed overall trends over the 10-year period in percentage of visits with anticholinergic prescriptions using logistic regression models. Survey year was the main predictor variable, and we combined years into 2-year intervals, assigning values ranging from 1 to 5 (152005-06, 252007-08, etc.). We transformed this variable by subtracting 1 and dividing by 4, resulting in values between 0 and 1, which allowed us to interpret the odds ratio (OR) as the change in the odds of anticholinergic prescriptions over the 10-year period. We repeated these analyses stratified according to physician specialty and anticholinergic class. Lastly, we used a multivariable-adjusted logistic regression analysis to identify demographic and clinical correlates independently associated with high-risk (Table 1) . Of visits at which anticholinergics were prescribed, 53.1% were with a primary care provider, and 11.6% were with a psychiatrist, neurologist, or urologist. Table 3 shows the results of multivariable-adjusted logistic regression analysis, which was used to estimate the odds of receiving an anticholinergic medication independent of other factors. The odds of an older women receiving a high-risk anticholinergic prescription were 1.88 times as great as those of an older men (95% CI51.71-2.06, p<.001). The odds of receiving high-risk anticholinergic prescriptions were 1.21 times as great in the South as in the Northeast (95% CI51.05-1.39, p5.007). The odds of receiving a high-risk anticholinergic prescription were higher for psychiatry and urology visits than for primary care visits (p<.001).
National Trends of High-Risk Anticholinergic Prescriptions
Multivariable Logistic Regression Analysis
The odds of receiving a high-risk anticholinergic prescription was 5.14 times as great for older adults prescribed 6 or more concomitant medications as for those with fewer than 6 (95% CI54.66-5.68, p<.001). Overactive bladder or urinary incontinence, neuropathic pain, vertigo or motion sickness, and insomnia were independently associated with greater odds of receiving a high-risk anticholinergic prescription (p<.01).
DISCUSSION
This pharmacoepidemiological study investigated predictors of and national prescribing trends in high-risk anticholinergic medications in older adults in a nationally representative sample of office-based outpatient visits from 15 These marginal differences may be due to differences in data collection (e.g., individual vs visit level) or which medications were specifically included.
Of the selected medication classes, antidepressants were the most prevalent. A recent study that demonstrated a near doubling in antidepressant prescriptions from 2002 to 2012 corroborates this. 21 Because safer pharmacological alternatives with less anticholinergic activity are available for treatments of depression, anxiety, and insomnia, for example, safer prescribing practices should be encouraged. The multivariable logistic regression analysis shows demographic and clinical factors independently associated with the odds of receiving a strong, high-risk anticholinergic prescription. Consistent with previous studies, 15, 22 women and people in the South were more likely to receive a high-risk anticholinergic prescription. The regional variation may be because of differences in physician practices, patient preferences, or formulary structure.
Individuals with 6 or more concomitant medications prescribed at the sampled visit also had a greater likelihood of having a high-risk anticholinergic prescription. This may result in serious polypharmacy-related adverse drug events in older adults. Future research is needed to determine whether high-risk anticholinergic medications moderate the relationship between polypharmacy and outcomes. Such a finding would underscore the need for reduction in high-risk anticholinergic prescribing in older adults. In general, there was a greater likelihood of a highrisk anticholinergic medication being prescribed at a visit that involved a diagnosis often treated using an anticholinergic (e.g., urinary incontinence). The severity of these indications may justify prescribing anticholinergics in individuals, but the risk of these medications merits informed shared decision-making.
There are several limitations to this study. First, NAMCS does not capture visits at hospital-affiliated clinics and emergency departments (8.5% of all outpatient visits) and excludes prescriptions placed over the telephone. Second, NAMCS selected information based on a randomly selected visit, which may have resulted in incomplete prescription documentation. For instance, NAMCS does not capture anticholinergic that clinicians other than the physician at the sampled visit have prescribed. Third, because only generic names of prescribed medications are provided in the data, we excluded some drugs from the analysis (e.g., doxepin) because dosing information is needed to estimate their indications precisely. For these reasons, our findings may underestimate the magnitude of anticholinergic prescribing at all time points.
Despite the limitations, the strengths of our study include generalizability because of the use of nationally representative data. In particular, the NAMCS is one of few datasets that represent physician practice and Survey collected information (e.g., arthritis, congestive heart failure, diabetes).
prescribing patterns in office-based care at the national level. Despite previous studies that have examined the use of strong, high-risk anticholinergic use and negative outcomes (e.g., developing cognitive impairment and dementia, mortality) in older adults, the overall prescribing trends of these medications remained stable between 2006 and 2015. Our findings highlight that all types of physicians need to decrease prescribing of all classes of highrisk anticholinergic medications because safer alternatives are available. The findings from our study lay the foundation for future research to develop and implement better quality of care practices to reduce high-risk anticholinergic prescriptions in older adults. Sponsor's Role: The funding agencies had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
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